5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial.

doi:10.1016/j.jad.2018.06.035

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial.

Journal of affective disorders - 1 Oct 2018

Kao Wei-Tsung, Chang Chen-Lin, Lung For-Wey

Abstract excerpt

OBJECTIVES: To investigate whether the serotonin transporter (5-HTT or SERT or SLC6A4) mRNA level could be used as a biomarker of treatment response in patients with major depression treated with different antidepressants while controlling related factors. METHODS: One hundred and nineteen patients with major depression were recruited; all genotyped for the 5-HTT polymorphism concerning 5-HTTLPR, rs25531, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Depressive Disorder, Major

Share to Paroxetine

Share to RNA, Messenger

Share to Serotonin Plasma Membrane Transport Proteins

Share to Time Factors

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 29957477
DOI: 10.1016/j.jad.2018.06.035

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial.PMID 29957477Read ↗

Role of serotonin transporter and receptor gene polymorphisms in treatment response to selective serotonin reuptake inhibitors in major depressive disorder.Semantic proximity Read ↗

Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.Semantic proximity Read ↗

5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.Semantic proximity Read ↗

Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder.Semantic proximity Read ↗

Moderation of antidepressant response by the serotonin transporter gene.Semantic proximity Read ↗

Serotonin transporter gene expression predicts the worsening of suicidal ideation and suicide attempts along a long-term follow-up of a Major Depressive Episode.Semantic proximity Read ↗

Sequence analysis of the serotonin transporter and associations with antidepressant response.Semantic proximity Read ↗

Serotonin transporter gene polymorphisms and treatment-resistant depression.Semantic proximity Read ↗

Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapySemantic proximity Read ↗

Effects of serotonin transporter and receptor polymorphisms on depression.Semantic proximity Read ↗

Serotonin transporter gene polymorphisms and sertraline response in major depression patients.Semantic proximity Read ↗

The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.